JP2023523218A5 - - Google Patents

Info

Publication number
JP2023523218A5
JP2023523218A5 JP2022563971A JP2022563971A JP2023523218A5 JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5 JP 2022563971 A JP2022563971 A JP 2022563971A JP 2022563971 A JP2022563971 A JP 2022563971A JP 2023523218 A5 JP2023523218 A5 JP 2023523218A5
Authority
JP
Japan
Application number
JP2022563971A
Other languages
Japanese (ja)
Other versions
JP2023523218A (ja
JPWO2021214658A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2021/053254 external-priority patent/WO2021214658A1/en
Publication of JP2023523218A publication Critical patent/JP2023523218A/ja
Publication of JP2023523218A5 publication Critical patent/JP2023523218A5/ja
Publication of JPWO2021214658A5 publication Critical patent/JPWO2021214658A5/ja
Pending legal-status Critical Current

Links

JP2022563971A 2020-04-22 2021-04-20 ヘテロ二量体ヒトインターロイキン-15(hetIL-15)の医薬組成物及び医薬製品 Pending JP2023523218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063013801P 2020-04-22 2020-04-22
US63/013,801 2020-04-22
PCT/IB2021/053254 WO2021214658A1 (en) 2020-04-22 2021-04-20 Pharmaceutical compositions and pharmaceutical products of heterodimeric human interleukin-15 (hetil-15)

Publications (3)

Publication Number Publication Date
JP2023523218A JP2023523218A (ja) 2023-06-02
JP2023523218A5 true JP2023523218A5 (https=) 2024-04-30
JPWO2021214658A5 JPWO2021214658A5 (https=) 2024-04-30

Family

ID=75639945

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022563971A Pending JP2023523218A (ja) 2020-04-22 2021-04-20 ヘテロ二量体ヒトインターロイキン-15(hetIL-15)の医薬組成物及び医薬製品

Country Status (14)

Country Link
US (1) US20210330747A1 (https=)
EP (1) EP4138782A1 (https=)
JP (1) JP2023523218A (https=)
KR (1) KR20230004655A (https=)
CN (1) CN115443127A (https=)
AR (1) AR122428A1 (https=)
AU (1) AU2021260989A1 (https=)
BR (1) BR112022020973A2 (https=)
CA (1) CA3178895A1 (https=)
CO (1) CO2022014867A2 (https=)
IL (1) IL297326A (https=)
MX (1) MX2022013352A (https=)
TW (1) TW202214290A (https=)
WO (1) WO2021214658A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118284620A (zh) * 2021-11-18 2024-07-02 山东先声生物制药有限公司 一种il-15突变体融合蛋白药物组合物
KR20250144433A (ko) * 2023-02-14 2025-10-10 아크론 바이오프로덕츠 엘엘씨 생체내 이용을 위한 인터루킨 제형물
CN117883565A (zh) * 2023-12-25 2024-04-16 中山大学 沙美特罗和pd-1抗体联用在制备治疗黑色素瘤的药物中的应用
WO2025206413A1 (en) * 2024-03-28 2025-10-02 The University Of Tokyo Protein-enclosing polymeric complexes

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
EP3263581B2 (en) 2005-05-17 2025-07-09 University of Connecticut Compositions and methods for immunomodulation in an organism
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
WO2009090189A1 (en) * 2008-01-15 2009-07-23 Abbott Gmbh & Co.Kg Powdered protein compositions and methods of making same
KR101577849B1 (ko) 2008-08-22 2015-12-15 마그나 시팅 인크. 감소된 백래쉬를 갖는 디스크 리클라이너
CN104689426B (zh) * 2009-10-21 2018-10-02 欧文蒙福德有限公司 自动注射器
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
EP2958588B1 (en) * 2013-02-22 2017-08-23 CureVac AG Combination of vaccination and inhibition of the pd-1 pathway
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
WO2017177063A1 (en) * 2016-04-06 2017-10-12 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Use of heterodimeric il-15 in adoptive cell transfer
UA125971C2 (uk) * 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
EP3810171B1 (en) * 2018-06-22 2025-07-09 Cugene Inc. Novel interleukin-15 (1l-15) fusion proteins and uses thereof
JP2022530130A (ja) * 2019-04-26 2022-06-27 ルビウス セラピューティクス, インコーポレイテッド 除核赤血球細胞を含む緩衝組成物

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
JP2023523218A5 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021015500A2 (https=)
BR102020022030A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021016837A2 (https=)
BR102021015566A2 (https=)
BR102021015450A8 (https=)
BR102021015220A2 (https=)
BR102021015247A2 (https=)
BR102021014044A2 (https=)
BR102021014056A2 (https=)